Search

Your search keyword '"Xercavins, J"' showing total 213 results
Start Over Author "Xercavins, J"
213 results on '"Xercavins, J"'

9. Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease

Author

Llaurado, M, Ruiz, A, Majem, B, Ertekin, T, Colas, E, Pedrola, N, Devis, L, Rigau, M, Sequeiros, T, Montes, M, Garcia, M, Cabrera, S, Gil-Moreno, A, Xercavins, J, Castellvi, J, Garcia, A, Cajal, SRY, Moreno, G, Alameda, F, Vazquez-Levin, M, Palacios, J, Prat, J, Doll, A, Matias-Guiu, X, Abal, M, and Reventos, J

Subjects
Treatment, Mice, Endometrial carcinoma, Molecular genetics, Aspirates, Target therapy
Abstract

Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometria I tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC. (C) 2011 Published by Elsevier Ireland Ltd.

Published
2012

10. Surgery improves survival in elderly with breast cancer. A study of 465 patients in a single institution

Author

Cortadellas, T., primary, Córdoba, O., additional, Gascón, A., additional, Haladjian, C., additional, Bernabeu, A., additional, Alcalde, A., additional, Esgueva, A., additional, Rodriguez-Revuelto, R., additional, Espinosa-Bravo, M., additional, Díaz-Botero, S., additional, Xercavins, J., additional, Rubio, I.T., additional, and Gil-Moreno, A., additional

Published
2015
Full Text
View/download PDF

12. Malignant vulvo-vaginal melanoma: a report of 7 cases

Author

González-Bosquet, J., Ángel García-Jiménez, Gil Moreno, A., and Xercavins, J.

Subjects
Aged, 80 and over, Vaginal Neoplasms, Vulvar Neoplasms, Humans, Lymph Node Excision, Female, Middle Aged, Melanoma, Aged
Abstract

To evaluate the clinical outcome of patients suffering from primary vulvo-vaginal malignant melanoma retrospective review of clinical and pathological data of six patients with vulvar malignant melanoma and one patient with vaginal melanoma was done. Patients were staged using the 1988 FIGO histological classification for vulvar cancer, and the 1992 American Joint Committee on Cancer (AJCC) classification for malignant melanoma of the skin. Clinical features, type of surgery, adjuvant therapy, recurrences, distant metastasis, and survival were recorded. Of 174 primary cancers of the vulva, six were malignant melanomas (3.4%), the second most common cause of vulvar cancer. Within the same period, only one primary vaginal melanoma was detected among 57 primary vaginal cancers (1.7%). The median age of all patients was 71 (range 61-84). We performed different surgical procedures, including a radical local excision of the lesion in the vaginal melanoma, a radical hemivulvectomy in one case, a radical vulvectomy in an other case, and a radical vulvectomy with lymph node dissection en bloc in three cases. According to the 1988 FIGO classification for vulvar carcinomas, three patients were diagnosed as stage I and four as stage III melanomas; and using the 1992 AJCC classification for malignant melanoma of the skin, all patients were staged as stage III. Two out of five patients, with a follow-up longer than two years, continued to live and were disease free at the last check-up (40%): the rest of them (60%) died of disease 2.9 months after the diagnosis of the distant metastasis. Vulvo-vaginal malignant melanomas are neoplasias with a very poor prognosis and a short period of time between the detection of distant metastasis and death. Although treatment is not clear in vaginal melanoma, the most accepted treatment in vulvar melanomas is the radical local excision of the lesion with a homolateral inguinofemoral lymphadenectomy.

Published
1997

19. Abstract P5-14-14: Benefit of Metallic Marker for Tumor Localization in Breast Cancer Patients Treated with Breast Conservative Surgery after Neoadjuvant Treatment. Comparative Study of Tumor Localization Markers

Author

Espinosa-Bravo, M, primary, Esgueva, A, additional, Sao, Avilés A, additional, Córdoba, O, additional, Cortadellas, T, additional, Mendoza, C, additional, Rodriguez, J, additional, Rubio, IT, additional, and Xercavins, J., additional

Published
2010
Full Text
View/download PDF

29. Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress

Author

Monge, M., primary, Colas, E., additional, Doll, A., additional, Gil-Moreno, A., additional, Castellvi, J., additional, Diaz, B., additional, Gonzalez, M., additional, Lopez-Lopez, R., additional, Xercavins, J., additional, Carreras, R., additional, Alameda, F., additional, Canals, F., additional, Gabrielli, F., additional, Reventos, J., additional, and Abal, M., additional

Published
2009
Full Text
View/download PDF

31. Novel molecular profiles of endometrial cancer—new light through old windows

Author

Doll, A., primary, Abal, M., additional, Rigau, M., additional, Monge, M., additional, Gonzalez, M., additional, Demajo, S., additional, Colás, E., additional, Llauradó, M., additional, Alazzouzi, H., additional, Planagumá, J., additional, Lohmann, M.A., additional, Garcia, J., additional, Castellvi, S., additional, Cajal, J. Ramon y, additional, Gil-Moreno, A., additional, Xercavins, J., additional, Alameda, F., additional, and Reventós, J., additional

Published
2008
Full Text
View/download PDF

36. 201

Author

Guerra Perez, T., primary, Suarez, E., additional, Herrero, E., additional, Garcia, A., additional, and Xercavins, J., additional

Published
2005
Full Text
View/download PDF

47. Out-of-protocol concurrent use of cisplatin and radiation therapy in locally advanced cervical cancer: feasibility and survival.

Author

Mancebo, G., Gil-Moreno, A., Verges, R., MartInez-Palones, J. M., Checa, M. A., Carreras, J. M. R., Giralt, J., and Xercavins, J.

Abstract

The article presents a study which explores the response rates and overall survival of patients in cisplatin-based chemotherapy during radiation therapy as a treatment for the locally advanced cervical cancer. The response of the patients who have received the treatment were evaluated three months after the end of the treatment. The result suggests that using cisplatin helps patients survive cervical cancer.

Published
2010

50. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility.

Author

Esteller, M, Garcia, A, Martinez-Palones, J M, Xercavins, J, and Reventos, J

Abstract

We describe here a case-control study to identify associations between polymorphisms at the methylenetetrahydrofolate reductase (MTHFR) and cytochrome P-450 1A1 (CYP1A1) genes and susceptibility to endometrial cancer. Accordingly, genotype frequencies in 80 endometrial carcinoma patients were compared with frequencies in 60 controls. DNA analysis suggest a significantly increased endometrial cancer risk with an alanine to valine substitution at nucleotide 677 of MTHFR gene with an odds ratio of 2.8 (95% confidence interval: 1.36-6.14, P = 0.002). Moreover, the tumors from patients with the valine allele were more undifferentiated (P = 0.03). On the other hand, a recently described mutation in exon 7 of CYP1A1 gene (threonine exchanged to asparagine in codon 461) showed a strong association with endometrial cancer risk with an odds ratio of 6.36 (95% confidence interval: 1.99-26.5, P = 0.0004). Thus, this study suggests that polymorphisms at MTHFR and a novel CYP1A1 variant could influence susceptibility to endometrial cancer, although larger sample sizes would be required to corroborate these findings. [ABSTRACT FROM PUBLISHER]

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results